Clinic Directory — coming soon. Are you an Australian peptide clinic?Apply to be listed →
Independent · Australian · Education only — not medical adviceAboutEditorial standardsHow we review
HomeEncyclopediaThymosin Alpha-1

Thymosin Alpha-1

Immune-modulating peptide

Compounded use

What it is

An immune-modulating peptide approved as a medicine in some overseas markets.

What the evidence shows

It has approved indications and clinical use in some overseas markets. In Australia it is not broadly registered, and the everyday "immune-boost" framing is not an approved use.

Safety & reported risks

Where accessed under supervision, risks are managed by the prescriber. Compounded peptides are subject to tightened TGA rules and quality considerations.

Status in Australia

Not broadly ARTG-registered. Where it is accessed in Australia, this is prescriber-led via compounding.

How it’s lawfully accessed

Limited and supervised — accessed, where appropriate, through a prescriber and compounding rather than general supply.

Related peptides

BPC-157Body Protection CompoundNot ARTG-approvedLL-37Cathelicidin antimicrobial peptideResearch

Sources & further reading

This entry is general information about Thymosin Alpha-1, not a recommendation to use it. We don’t provide dosing, protocols or sourcing. Speak to a registered practitioner.

Written by The Peptides.au editorial team
Editorial review Checked against current TGA, ARTG and AHPRA public guidance
Last updated 1 June 2026

This is general education, not medical advice. Peptides.au does not sell, supply, recommend or promote any product or clinic. Always speak with a registered Australian health practitioner before making any health decision.